11/5/2026

speaker
Conference Call Operator
Operator

Good afternoon, ladies and gentlemen, and welcome to the Fulton Genetics Q3 2026 conference call and webcast call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 5, 2026. I would now like to turn the call over to Lauren Sloan. Please go ahead.

speaker
Lauren Sloan
Investor Relations

Good afternoon and welcome to Fulgent's third quarter 2026 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer, Paul Kim, Chief Financial Officer, and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the investor relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the investor relations section of the company's website. Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views, expectations, and assumptions, which may prove to be incorrect. As a result, matters discussed in any forward-looking statements are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ from those described in the forward-looking statements. The company assumes no obligation to update any of the forward-looking statements it may make today to reflect actual results or changes in expectations. Listeners should not rely on any forward-looking statements as predictions of future events and should listen to management remarks today with the understanding that actual events, including the company's actual future results, may be material different from what is described in or implied by these forward-looking statements. Please review the more detailed discussions related to these forward-looking statements, including the discussions of some of the risk factors that may cause results to differ from those described in the forward-looking statements contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10-K for the year ended December 31st, 2025 and subsequently filed reports which are available on the company's investor relations website. Management's remarks including discussions of non-GAAP profit, loss, operating expense, margin, earnings and earnings per share and adjusted EBITDA contain financial measures not prepared in accordance with accounting principles generally accepted in the United States or GAAP. Management has presented these non-GAAP financial measures because it believes They may be useful for investors for various reasons, but these measures should not be viewed as a substitute for or superior to the company's financial results in accordance with GAAP. Please see the company's press release discussing its financial results for the third quarter of 2026 for more information, including the description of how the company calculates non-GAAP income and loss, non-GAAP earnings and loss per share, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating profit and loss, and margin and Adjusted EBITDA in a reconciliation of these financial measures to income and loss, earnings loss per share and operating margin, the most directly comparable GAAP financial measures. The company does not provide reconciliation of forward-looking non-GAAP measures to the most directly comparable GAAP measures because the information necessary to calculate such reconciliations including equity-based compensation, tax effects, acquisition-related items and potential impairments Any of which may be material is unavailable on a forward-looking basis without unreasonable effort, and the probable significance of those items cannot be predicted. With that, I'd now like to turn the call over to Ming. Please go ahead.

speaker
Ming Hsieh
Chief Executive Officer

Thank you, Lauren. I will start with some comments on our two business lines. Then Brandon will reveal our product and go-to-market updates for our laboratory service business. and Paul will conclude with the financials and outlook before we take your questions. I am pleased with the momentum in our therapeutic development business as we progress on our clinical pipeline. We are seeing encouraging clinical data from our proprietary nano drug delivery platform which powers both FID-07 and FID-022. Let me share the recent updates from FID-07 and then share the progress we have made with FID-022. As a reminder, Fulgine has taken a different approach with FID-07. FID-07 is a nanoencapsulated tactic textile developed under Fulgine's clean chemo platform. The platform is designed to reduce toxicity typically associated with conventional chemotherapy while maintaining or improving efficacy. A profile full gene BD is preferable in combination oncology regimens. Starting with FID07, with the majority of Phase II complete, we have the end of a Phase II meeting with the FDA in August. We look forward to sharing more with you later this year. Our Phase III study is in preparation. We are encouraged by our clinical trial progress achieved so far, and I believe entering the Phase III registration trial is an important step toward the potential commercialization of FID-07 for the treatment of recurrence of metastatic head and neck zirconia cell carcinoma patients who currently have very few effective treatment options. We continue to approach conversations with the partners who bring both resource and strategies alignment. In the third quarter, we were pleased with the momentum of our second clinical candidate, FID022. With the phase one dosing escalation at the phase dosing level ongoing, we expect to determine the maximum tolerance dose level in the first half of next year. FID-022 is a nanoencapsulated SN38 for treatment of solid tumors including potentially colon, pancreatic, ovarian, and bile duct cancers. Please note that both FID-07 and FID-022 are derived from the same proprietary clean chemo delivery platform patented and fully owned by Folgen. Similar to FID-07, FID 022 can also be used in various oncology drug combinations. In conclusion, we believe our common platform strategy is making meaningful progress. We're seeing greater potential in commercializing FID 07 and FID 022 to drive a large and growing market. In laboratory services business, We continue to see our AI and digital pathology solution work at an accelerated pace and are continuing to expand our AI portfolios. We are pleased with the progress we have made to address billing and revenue cycle management delays, which continue to affect our third quarter results and our team's ability to work effectively to deliver the improvement to our collection rate. I would like to thank our employees, partners, and stakeholders for your hard work and loyalty. I will now turn over the call to Brandon Perthuis, our Chief Commercial Officer, to talk more about our laboratory service business. Brandon?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API